Literature DB >> 3383444

Quantification of soluble serum HLA class I antigens in healthy volunteers and AIDS patients.

A Ferreira1, M L Villar, J C Alvarez Cermeño, Y Revilla, M C García Rodriguez, G Fontán, P González-Porqué.   

Abstract

A solid-phase enzyme immunoassay (ELISA) has been used to quantify human soluble Class I histocompatibility antigens in serum samples from voluntary blood donors and AIDS patients. Statistical analysis of the results showed significantly raised levels (p less than 0.01) of free HLA Class I in sera from AIDS patients (2.95 +/- 1.80 micrograms/ml) when compared with the blood donors (1.06 +/- 0.6 micrograms/ml). The assay is specific, reproducible and easy to perform. Potential uses of this determination are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3383444     DOI: 10.1016/0009-8981(88)90387-7

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  Soluble class I histocompatibility antigens (s-HLA) and beta 2-microglobulin at delivery.

Authors:  A Ferreira; M C García Rodríguez; F Omeñaca; A Jiménez; L M Villar; P Gonzalez-Porqué; G Fontán
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

Review 2.  Soluble major histocompatibility complex molecules in immune regulation: highlighting class II antigens.

Authors:  Katerina Bakela; Irene Athanassakis
Journal:  Immunology       Date:  2017-12-11       Impact factor: 7.397

3.  Soluble class I antigens in serum and CSF of patients with varicella-zoster virus meningitis.

Authors:  J Alvarez-Cermeño; J M Echevarría; L M Villar; I Lázaro; A Bootello; P González-Porque
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-10       Impact factor: 10.154

4.  Soluble HLA-I (s-HLA-I) synthesis in systemic lupus erythematosus.

Authors:  Irena Adamashvili; Robert Wolf; Donnie Aultman; Edgar L Milford; Stephen Jaffe; Vicky Hall; Thomas Pressly; Alireza Minagar; Roger Kelley
Journal:  Rheumatol Int       Date:  2003-07-23       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.